Establishment of cultured primary acral melanoma cells and animal models for Chinese patients.


Journal

Pigment cell & melanoma research
ISSN: 1755-148X
Titre abrégé: Pigment Cell Melanoma Res
Pays: England
ID NLM: 101318927

Informations de publication

Date de publication:
11 2021
Historique:
revised: 06 05 2021
received: 23 02 2021
accepted: 27 05 2021
pubmed: 8 6 2021
medline: 29 3 2022
entrez: 7 6 2021
Statut: ppublish

Résumé

Acral melanoma is the major subtype of melanoma in Chinese patients. However, a majority of current studies focused on non-acral melanoma. Most immortalized melanoma cell lines and primary cells were not from acral melanoma. Besides, there are rarely reports about methods for establishing primary acral melanoma cell cultures and related animal models. Here, we present four new human primary acral melanoma cell lines. To determine the mutational profile of the established primary melanoma cells for future targeted use, we performed exome sequencing. We next examined cell proliferation of the primary acral melanoma cells by colony-formation assays and CCK8 assay. We also evaluated the proliferative and metastatic potential of XYAM-4 in vivo. We report a detailed protocol for establishing cultured primary acral melanoma cells for Chinese patients and related animal models. We also summarize the features in our acral melanoma cell lines and the existing acral melanoma cell lines. This will provide an effective research tool for research on drug responses and individualized treatment for Chinese patients and comparative studies of melanomas between western and Chinese populations.

Identifiants

pubmed: 34097822
doi: 10.1111/pcmr.12996
pmc: PMC9291188
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1131-1137

Informations de copyright

© 2021 The Authors. Pigment Cell & Melanoma Research published by John Wiley & Sons Ltd.

Références

J Invest Dermatol. 2018 Feb;138(2):384-393
pubmed: 28870692
Pigment Cell Melanoma Res. 2021 Nov;34(6):1131-1137
pubmed: 34097822
EBioMedicine. 2018 Jun;32:119-124
pubmed: 29793878
Mod Pathol. 2015 Aug;28(8):1033-42
pubmed: 26022451
Cancer Sci. 2007 Jul;98(7):958-63
pubmed: 17488338
J Invest Dermatol. 2019 Jul;139(7):1526-1534
pubmed: 30710577
Pigment Cell Melanoma Res. 2012 Jul;25(4):488-92
pubmed: 22578220
Nature. 2017 May 11;545(7653):175-180
pubmed: 28467829
Br J Dermatol. 2020 May;182(5):1205-1213
pubmed: 31408190
J Invest Dermatol. 2018 Apr;138(4):933-945
pubmed: 29191620

Auteurs

Rui Hu (R)

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Hunan Engineering Research Center of Skin Health and Disease, Changsha, China.
Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China.

Shuang Zhao (S)

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Hunan Engineering Research Center of Skin Health and Disease, Changsha, China.
Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China.

Juan Su (J)

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Hunan Engineering Research Center of Skin Health and Disease, Changsha, China.
Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China.

Xiang Chen (X)

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Hunan Engineering Research Center of Skin Health and Disease, Changsha, China.
Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China.

Mingzhu Yin (M)

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Hunan Engineering Research Center of Skin Health and Disease, Changsha, China.
Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH